History of Changes for Study: NCT03690115
Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients (PONALLO)
Latest version (submitted August 4, 2021) on
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 September 27, 2018 None (earliest Version on record)
2 August 31, 2019 Recruitment Status, Study Status, Contacts/Locations and Oversight
3 August 4, 2021 Study Status
Comparison Format:

Scroll up to access the controls

Study NCT03690115
Submitted Date:  September 27, 2018 (v1)

Open or close this module Study Identification
Unique Protocol ID: P1701_ PONALLO
Brief Title: Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients (PONALLO)
Official Title: Phase 2 Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients: the PONALLO Trial."
Secondary IDs:
Open or close this module Study Status
Record Verification: September 2018
Overall Status: Not yet recruiting
Study Start: October 2018
Primary Completion: December 2021 [Anticipated]
Study Completion: May 2022 [Anticipated]
First Submitted: April 4, 2018
First Submitted that
Met QC Criteria:
September 27, 2018
First Posted: October 1, 2018 [Actual]
Last Update Submitted that
Met QC Criteria:
September 27, 2018
Last Update Posted: October 1, 2018 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Versailles Hospital
Responsible Party: Principal Investigator
Investigator: Patrice Chevallier
Official Title: MD
Affiliation: Nantes University Hospital
Open or close this module Oversight
U.S. FDA-regulated Drug: No
U.S. FDA-regulated Device: No
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary:

Recent advances in acute myeloid leukemia (AML) have been characterized by a better understanding of disease biology. As such, FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) have been recognized as conferring a poor prognosis. The FLT3-ITD molecular mutation is observed in about one-quarter of patients diagnosed with AML. Patients presenting with this abnormality are referred for early allogeneic stem-cell transplantation (allo-SCT). However, some data suggest that FLT3-ITD remains associated with a poor prognosis even after allo-SCT because of higher risk of relapse and strategies for preventing relapse in the post-transplant setting are required (Hu et al, Expert Rev Hematol, 2014). For example, in a large cohort of patients (Brunet et al, JCO, 2012), the incidence of relapse for FLT3-ITD AML patients after allo-SCT was 30% at 2-years, significantly higher compared to FLT3-ITD negative patients (p=0.006).

Ponatinib (Iclusig®) is an orally available, tyrosine kinase inhibitor with a unique binding mechanism allowing inhibition of BCR-ABL kinases, including those with the T315I point mutation. Ponatinib also has in vitro inhibitory activity against a discrete set of kinases implicated in the pathogenesis of other hematologic malignancies, including FLT3, KIT, fibroblast growth factor receptor 1 (FGFR1), and platelet derived growth factor receptor α (PDGFRα). In vitro activity of ponatinib in AML has been already demonstrated (Gozgit et al, Mol Cancer Ther, 2011; Smith et al, Blood 2013). If some trials are on-going to test ponatinib alone or in combination with chemotherapy in FLT3-ITD AML (, no study is dedicated to the use of ponatinib in the post-transplant setting in order to prevent relapse in these patients.

The main goal of this study will be to determine the maximal tolerated dose (MDT) of ponatinib after allo-SCT in FLT3-ITD AML patients, then to investigate the efficacy of ponatinib in a larger cohort of patients

Detailed Description:
Open or close this module Conditions
Conditions: Leukemia, Myeloid, Acute
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 2
Interventional Study Model: Single Group Assignment
Number of Arms: 1
Masking: None (Open Label)
Allocation: N/A
Enrollment: 77 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: Experimental
Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient
Drug: Ponatinib 30 MG
Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Relapse incidence at 2 years from transplant
[ Time Frame: 2 years ]

Secondary Outcome Measures:
1. Overall survival
[ Time Frame: 2 years ]

time interval from the graft (day 0) until the date of last follow-up or death
2. Leukemia free survival
[ Time Frame: 2 years ]

time interval from the date of the graft (day 0) until the date of last follow-up, death or relapse
3. Non-relapse mortality (NRM)
[ Time Frame: day 100 ]

incidence of mortality due to all causes except relapse after transplant, considering that cause of death for patients having relapsed but dying from another cause is relapse
4. Acute and chronic GVHD
[ Time Frame: 2 years ]

NIH score
5. Influence of Ponatinib on Immune reconstitution PB lymphocyte cells
[ Time Frame: 1 years ]

an immunophenotype of PB lymphocytes will be performed by flow cytometry at +3, +6, +9 and +12 months post-transplant to study the reconstitutions of CD3, CD4 and CD8 T cells, B and NK cells. The results will be expressed as absolute counts (Giga/L). We want to establish the potential influence of ponatinib on the reconstitution of these cells
6. Inflence of Ponatinib on Chimerism of Donor peripheral blood and CD3 T cells
[ Time Frame: 1 years ]

Donor peripheral blood and CD3 T cells chimerism will be studied using molecular markers and RT-PCR at day +30, +60, +90, and +6, +12 months post-transplant. We want to establish the potential influence of ponatinib on the chimerism post-transplant.
7. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
[ Time Frame: 2 years ]

Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age: 70 Years
Sex: All
Gender Based:
Accepts Healthy Volunteers: No

Inclusion Criteria:

  • Engraftment
  • Controlled GVHD
  • Positive FLT-3 ITD AML in cytologic complete remission
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status < 2
  • Have adequate renal function: Serum creatinine ≤ 1.5 × upper limit of normal (ULN) for institution
  • Have adequate hepatic function: Total serum bilirubin ≤ 1.5 × ULN, unless due to Gilbert's syndrome; Alanine aminotransferase (ALT) ≤ 2.5 × ULN, or ≤ 5 × ULN if leukemic infiltration of the liver is present ; Aspartate aminotransferase (AST) ≤ 2.5 × ULN, or ≤ 5 × ULN if leukemic infiltration of the liver is present
  • Have normal pancreatic status: Serum lipase and amylase ≤ 1.5 × ULN
  • Have normal QTcF interval on screening electrocardiogram (ECG) evaluation,defined as QTcF of ≤ 450 ms in males or ≤ 470 ms in females.
  • Platelets ≥ 100 Giga/l; Neutrophils ≥ 1 Giga/l
  • Have a negative pregnancy test documented prior to enrollment (for females of childbearing potential).
  • Agree to use an effective form of contraception with sexual partners throughout study participation (for female and male patients who are fertile).
  • Provide written informed consent.
  • Be willing and able to comply with scheduled visits and study procedures.

Exclusion Criteria:

  • HIV positive, active Hepatitis B or C
  • Childbearing or childbreast feeding women
  • Women or men without effective contraceptive barrier if needed
  • Previous myocardial infarction, or cerebral vascular accident, pancreatitis
  • Respiratory insufficiency defined as DLCO <40% of the corrected value
  • Creatinine clearance ≤ 50ml/min
  • Contra-indication to ponatinib
  • Previous or concurrent second malignancy except for adequately treated basal cell carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively treated solid cancer, with no evidence of disease for at least 2 years
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • Patients at high or very high risk of cardiovascular disease with any of the following
    1. Established cardiovascular disease Cardiac disease:
      • Congestive heart failure greater than class II NYHA or
      • Left ventricular ejection fraction (LVEF) < 50% or
      • Unstable angina (anginal symptoms at rest) or
      • New onset angina (began within the last 3 months) or
      • Myocardial infarction, coronary/peripheral artery disease, congestive heart failure, cerebrovascular accident including transient ischemic attack within the past 12 months or
      • History of thrombolic or embolic events Arrhythmias
      • Any history of clinically significant cardiac arrhythmias requiring anti-arrhythmic therapy.
    2. Diabetes Mellitus,
    3. Arterial Hypertension,
      • Uncontrolled hypertension defined as systolic blood pressure greater than 140 mmHg or diastolic pressure greater than 90 mmHg, despite optimal medical management and optimal measurement (
      • Any history of hypertension with
      • Hypertensive encephalopathy
      • Posterior leucoencephalopathy
      • Aortic or artery dissection
    4. Familial dysplipidemia.
    5. Taking medications that are known to be associated with Torsades de Pointes (see
Open or close this module Contacts/Locations
Central Contact Person: Laure MORISSET
Telephone: +33139239785
Locations: France
CHU NAgers
Angers, France
Contact:Contact: François
CHu Brest
Brest, France
Contact:Contact: Guillerm
CHU Caen
Caen, France
Contact:Contact: Chantepie
CHU Clermont Ferrand
Clermont Ferrand, France
Contact:Contact: Guieze
CHU Grenoble
Grenoble, France
Contact:Contact: Bulabois
CHU Lille
Lille, France
Contact:Contact: Yakoub Agha
CHU Limoges
Limoges, France
Contact:Contact: Turlure
Nantes, France
Contact:Contact: Patrice Chevallier
Hopital St Antoine
Paris, France
Contact:Contact: Mothy
Hopital St Louis
Paris, France
Contact:Contact: Regis Peffault de la tour
CHu Lyon
Pierre-Bénite, France
Contact:Contact: Labussière
CHU Poitiers
Poitiers, France
Contact:Contact: Maillard
CRLC Toulouse
Toulouse, France
Contact:Contact: Huynh
CHU Nancy
Vandœuvre-lès-Nancy, France
Contact:Contact: Rubio
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services